These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37258659)

  • 1. Quantitative response of macular neovascularisation to loading phase of aflibercept in neovascular age-related macular degeneration.
    Montesel A; Hagag AM; Chandra S; Muhammed RP; Thottarath S; Chandak S; Sivaprasad S
    Eye (Lond); 2023 Dec; 37(17):3648-3655. PubMed ID: 37258659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration].
    Fursova AZ; Nikulich IF; Dmitrieva EI; Gusarevich OG; Derbeneva AS; Vasilyeva MA; Kozhevnikova OS; Kolosova NG; Rabota FK
    Vestn Oftalmol; 2023; 139(6):50-58. PubMed ID: 38235630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4.
    Montesel A; Pakeer Muhammed R; Chandak S; Kazantzis D; Thottarath S; Chandra S; Chong V; Burton BJL; Menon G; Pearce I; McKibbin M; Kotagiri A; Talks J; Grabowska A; Ghanchi F; Gale R; Giani A; Yamaguchi TCN; Sivaprasad S
    Eye (Lond); 2024 Sep; 38(13):2596-2602. PubMed ID: 38653751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
    Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
    Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.
    Monés J; Biarnés M;
    Eur J Ophthalmol; 2020 Sep; 30(5):1082-1090. PubMed ID: 31088111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of vascular and fluid-related parameters in neovascular age-related macular degeneration using deep learning.
    Schranz M; Told R; Hacker V; Reiter GS; Reumueller A; Vogl WD; Bogunovic H; Sacu S; Schmidt-Erfurth U; Roberts PK
    Acta Ophthalmol; 2023 Feb; 101(1):e95-e105. PubMed ID: 35912717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
    Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD.
    Minnella AM; Centini C; Gambini G; Savastano MC; Pagliei V; Falsini B; Rizzo S; Ciasca G; Maceroni M
    Adv Ther; 2022 Jul; 39(7):3248-3261. PubMed ID: 35597837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LONG-TERM MORPHOLOGIC CHANGES IN MACULAR NEOVASCULARIZATION UNDER AFLIBERCEPT TREATMENT WITH A TREAT-AND-EXTEND REGIMEN.
    Nakano Y; Takeuchi J; Horiguchi E; Ota H; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Retina; 2023 Mar; 43(3):412-419. PubMed ID: 36730570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two year outcome in treatment-naive patients with neovascular age-related macular degeneration (nAMD) using an individualized regimen of Aflibercept.
    Barakat A; Rufin V; Tran THC
    J Fr Ophtalmol; 2018 Sep; 41(7):603-610. PubMed ID: 30166233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using optical coherence tomography angiography in assessment of the anti-vascular endothelial growth factor effect for pathological vascular tissue in age-related macular degeneration and polypoidal choroidal vasculopathy.
    Shen YS; Cheng CK
    Eur J Ophthalmol; 2021 May; 31(3):1267-1280. PubMed ID: 32228025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months.
    Garweg JG; Gerhardt C; Kodjikian L; Pfister IB
    J Ocul Pharmacol Ther; 2017 Sep; 33(7):567-572. PubMed ID: 28557667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
    Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
    Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
    Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration.
    Kawashima Y; Hata M; Oishi A; Ooto S; Yamashiro K; Tamura H; Miyata M; Uji A; Ueda-Arakawa N; Tsujikawa A
    Am J Ophthalmol; 2017 Sep; 181():61-70. PubMed ID: 28669776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of Retinal Thickness and Swept-Source Optical Coherence Tomography Angiography Derived Vascular Changes in Patients with Neovascular Age-Related Macular Degeneration.
    Told R; Reiter GS; Schranz M; Reumueller A; Hacker V; Mittermueller TJ; Roberts PK; Sacu S; Schmidt-Erfurth U
    Curr Eye Res; 2021 Jul; 46(7):1002-1009. PubMed ID: 33211556
    [No Abstract]   [Full Text] [Related]  

  • 19. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY ASSESSMENT OF VASCULAR EFFECTS OCCURRING AFTER AFLIBERCEPT INTRAVITREAL INJECTIONS IN TREATMENT-NAIVE PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION.
    Mastropasqua L; Toto L; Borrelli E; Carpineto P; Di Antonio L; Mastropasqua R
    Retina; 2017 Feb; 37(2):247-256. PubMed ID: 27628926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.
    Roald AB; Aass HC; Moe MC
    Br J Ophthalmol; 2015 Dec; 99(12):1610-3. PubMed ID: 25966740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.